Please Wait...

COL4 // Type IV Collagen

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Type Collagen IV is encoded by six genes: COL4A1, COL4A2, COL4A3, COL4A4, COL4A5, and COL4A6 for the six collagen chain implicated in its composition: α1(IV) through α6(IV). The assembly of collagen IV network is highly regulated. Each of the six chains present the same features with three domains: short 7S N-Terminal, collagenous domain and non-collagenous domain (NC1) in C-terminal and can form three sets of helical molecules. Depending on the tissues the set of collagen type IV molecules is different. The α1.α1.α2(IV)-α1.α1.α2(IV) network is found in all basement membranes in the animal phyla, the α3.α4.α5(IV)-α3.α4.α5(IV) and the α1.α1.α2(IV)-α5.α5.α6(IV) are only found in mammalian basement membranes (Hudson et al., 2003). NC1 trimers also connect to form hexameric quaternary structure through head to head interaction and the collagen IV network is also formed through protomer-protomer interactions in the collagenous and covalent binding in the 7S domain (with four independent protomers)(Cummings and Hudson, 2014). Elevated serum and/or urinary content in Collagen IV can be found in patient with diabetic nephropathy and in some cancers (Banu et al., 1995; KINOSHITA et al., 2010; Nyström et al., 2015).

Bioclinica Lab employs a manual sandwich immunoassay for the measurement of Collagen IV in serum, plasma or urine.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Bioclinica contributions toward advancement of #Alzheimer's disease research & therapies showcased in 8 different s…
bioclinica (5 hours ago)
Bioclinica’s Joby John reflects on the #SCDM2018 Annual Conference & being a part a thriving community of clinical…
bioclinica (23 hours ago)
RT @bioclinica: Our own Jeff Heilbraun is in Tokyo nxt wk to lead a discussion at DIA’s Cardiac Safety Workshop in Japan. Jeff will give an…
bioclinica (Yesterday)
RT @Xtalks: Trends in #SitePayments: Insight into How CROs Can Gain a Competitive Edge This webinar will focus on the latest market researc…
bioclinica (Yesterday)
Great connecting w @bioclinica clients Odonate Therapeutics, Eisai, & PCI Biotech, at #ESMO18 #oncology…
bioclinica (Yesterday)
Our own Jeff Heilbraun is in Tokyo nxt wk to lead a discussion at DIA’s Cardiac Safety Workshop in Japan. Jeff will…
bioclinica (4 days ago)

Latest Blogs:

Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner